» Articles » PMID: 28133717

Dopamine Increases CD14CD16 Monocyte Transmigration Across the Blood Brain Barrier: Implications for Substance Abuse and HIV Neuropathogenesis

Overview
Date 2017 Jan 31
PMID 28133717
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

In human immunodeficiency virus-1 (HIV) infected individuals, substance abuse may accelerate the development and/or increase the severity of HIV associated neurocognitive disorders (HAND). It is proposed that CD14CD16 monocytes mediate HIV entry into the central nervous system (CNS) and that uninfected and infected CD14CD16 monocyte transmigration across the blood brain barrier (BBB) contributes to the establishment and propagation of CNS HIV viral reservoirs and chronic neuroinflammation, important factors in the development of HAND. The effects of substance abuse on the frequency of CD14CD16 monocytes in the peripheral circulation and on the entry of these cells into the CNS during HIV neuropathogenesis are not known. PBMC from HIV infected individuals were analyzed by flow cytometry and we demonstrate that the frequency of peripheral blood CD14CD16 monocytes in HIV infected substance abusers is increased when compared to those without active substance use. Since drug use elevates extracellular dopamine concentrations in the CNS, we examined the effects of dopamine on CD14CD16 monocyte transmigration across our in vitro model of the human BBB. The transmigration of this monocyte subpopulation is increased by dopamine and the dopamine receptor agonist, SKF 38393, implicating D1-like dopamine receptors in the increase in transmigration elicited by this neurotransmitter. Thus, elevated extracellular CNS dopamine may be a novel common mechanism by which active substance use increases uninfected and HIV infected CD14CD16 monocyte transmigration across the BBB. The influx of these cells into the CNS may increase viral seeding and neuroinflammation, contributing to the development of HIV associated neurocognitive impairments.

Citing Articles

Recent advances in nanotherapeutics for HIV-associated neurocognitive disorders and substance use disorders.

Lomas C, Dubey R, Perez-Alvarez G, Lopez Hernandez Y, Atmar A, Arias A Nanomedicine (Lond). 2025; 20(6):603-619.

PMID: 39963928 PMC: 11902879. DOI: 10.1080/17435889.2025.2461984.


Something to talk about; crosstalk disruption at the neurovascular unit during HIV infection of the CNS.

Galpayage Dona K, Benmassaoud M, Gipson C, McLaughlin J, Ramirez S, Andrews A NeuroImmune Pharm Ther. 2025; 3(2):97-111.

PMID: 39958876 PMC: 11823645. DOI: 10.1515/nipt-2024-0003.


Acute stimulation of PBMCs drives switch from dopamine-induced anti- to proinflammatory phenotype of monocytes only in women.

Fleige L, Capellino S Biol Sex Differ. 2025; 16(1):8.

PMID: 39901238 PMC: 11789415. DOI: 10.1186/s13293-025-00689-5.


The Impact of HIV on Early Brain Aging-A Pathophysiological (Re)View.

Lazar M, Moroti R, Barbu E, Chitu-Tisu C, Tiliscan C, Erculescu T J Clin Med. 2024; 13(23).

PMID: 39685490 PMC: 11642420. DOI: 10.3390/jcm13237031.


Identifying methamphetamine use predictors in HIV infection: Immune-dopaminergic signatures in peripheral leukocytes and the role of COMT genotype.

Basova L, Riley T, Franklin D, Delorme-Walker V, Lim W, Grant I Brain Behav Immun Health. 2024; 42:100873.

PMID: 39430881 PMC: 11490913. DOI: 10.1016/j.bbih.2024.100873.


References
1.
Iwakura Y, Wang R, Abe Y, Piao Y, Shishido Y, Higashiyama S . Dopamine-dependent ectodomain shedding and release of epidermal growth factor in developing striatum: target-derived neurotrophic signaling (Part 2). J Neurochem. 2011; 118(1):57-68. DOI: 10.1111/j.1471-4159.2011.07295.x. View

2.
Takamune Y, Ikebe T, Nagano O, Shinohara M . Involvement of NF-kappaB-mediated maturation of ADAM-17 in the invasion of oral squamous cell carcinoma. Biochem Biophys Res Commun. 2007; 365(2):393-8. DOI: 10.1016/j.bbrc.2007.11.010. View

3.
Spiller M, Broz D, Wejnert C, Nerlander L, Paz-Bailey G . HIV infection and HIV-associated behaviors among persons who inject drugs--20 cities, United States, 2012. MMWR Morb Mortal Wkly Rep. 2015; 64(10):270-5. PMC: 4584803. View

4.
Gonzalez-Scarano F, Martin-Garcia J . The neuropathogenesis of AIDS. Nat Rev Immunol. 2005; 5(1):69-81. DOI: 10.1038/nri1527. View

5.
Davis L, Hjelle B, Miller V, PALMER D, Llewellyn A, Merlin T . Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology. 1992; 42(9):1736-9. DOI: 10.1212/wnl.42.9.1736. View